{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:20:23Z","timestamp":1740136823190,"version":"3.37.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T00:00:00Z","timestamp":1539129600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Samsung Bioepis"},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13075-018-1728-3","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T09:24:12Z","timestamp":1539163452000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: results from BIOBADASER"],"prefix":"10.1186","volume":"20","author":[{"name":"on behalf of the BIOBADASER\u00a0study group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jos\u00e9","family":"Bethencourt Baute","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Sanchez-Piedra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolores","family":"Ruiz-Montesinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Medrano San Ildefonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Rodriguez-Lozano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Perez-Pampin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Manrique","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Rosell\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agust\u00ed","family":"Sellas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter Alberto","family":"Sifuentes-Giraldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Garc\u00eda-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Sanchez-Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"D\u00edaz-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jes\u00fas","family":"G\u00f3mez-Reino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagrario","family":"Bustabad Reyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,10]]},"reference":[{"issue":"2","key":"1728_CR1","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u20132.","journal-title":"J Rheumatol"},{"issue":"2","key":"1728_CR2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jbspin.2013.09.003","volume":"81","author":"S Thierry","year":"2014","unstructured":"Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine. 2014;81(2):112\u20137.","journal-title":"Joint Bone Spine"},{"key":"1728_CR3","doi-asserted-by":"crossref","unstructured":"Martinez Mengual L, Fernandez Menendez JM, Solis Sanchez G, Fernandez Diaz M, Fernandez Gonzalez N, Malaga Guerrero S: Epidemiological study of juvenile idiopathic arthritis in the last sixteen years in Asturias (Spain) [in Spanish]. An Pediatr (Barc) 2007, 66(1):24\u201330.","DOI":"10.1157\/13097354"},{"issue":"6","key":"1728_CR4","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3109\/03009741003742722","volume":"39","author":"C Modesto","year":"2010","unstructured":"Modesto C, Anton J, Rodriguez B, Bou R, Arnal C, Ros J, Tena X, Rodrigo C, Rotes I, Hermosilla E, et al. Incidence and prevalence of juvenile idiopathic arthritis in Catalonia (Spain). Scand J Rheumatol. 2010;39(6):472\u20139.","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"1728_CR5","first-page":"394","volume":"30","author":"SL Bowyer","year":"2003","unstructured":"Bowyer SL, Roettcher PA, Higgins GC, Adams B, Myers LK, Wallace C, Rennebohm R, Moore TL, Pepmueller PH, Spencer C, et al. Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. J Rheumatol. 2003;30(2):394\u2013400.","journal-title":"J Rheumatol"},{"issue":"12","key":"1728_CR6","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1002\/art.11337","volume":"48","author":"S Magni-Manzoni","year":"2003","unstructured":"Magni-Manzoni S, Rossi F, Pistorio A, Temporini F, Viola S, Beluffi G, Martini A, Ravelli A. Prognostic factors for radiographic progression, radiographic damage, and disability in juvenile idiopathic arthritis. Arthritis Rheum. 2003;48(12):3509\u201317.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1728_CR7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1136\/ard.2003.017053","volume":"64","author":"T Mason","year":"2005","unstructured":"Mason T, Reed AM, Nelson AM, Thomas KB. Radiographic progression in children with polyarticular juvenile rheumatoid arthritis: a pilot study. Ann Rheum Dis. 2005;64(3):491\u20133.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1728_CR8","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1136\/annrheumdis-2013-204641","volume":"74","author":"MH Otten","year":"2015","unstructured":"Otten MH, Anink J, Prince FH, Twilt M, Vastert SJ, ten Cate R, Hoppenreijs EP, Armbrust W, Gorter SL, van Pelt PA, et al. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register. Ann Rheum Dis. 2015;74(7):1379\u201386.","journal-title":"Ann Rheum Dis"},{"key":"1728_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1546-0096-12-13","volume":"12","author":"ML Stoll","year":"2014","unstructured":"Stoll ML, Cron RQ. Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatr Rheumatol Online J. 2014;12:13.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"6","key":"1728_CR10","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2165\/11532610-000000000-00000","volume":"12","author":"S Shenoi","year":"2010","unstructured":"Shenoi S, Wallace CA. Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review. Paediatr Drugs. 2010;12(6):367\u201377.","journal-title":"Paediatr Drugs"},{"issue":"25","key":"1728_CR11","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, Cuttica R, Ravelli A, Schneider R, Woo P, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385\u201395.","journal-title":"N Engl J Med"},{"issue":"10","key":"1728_CR12","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1002\/art.39234","volume":"67","author":"DJ Lovell","year":"2015","unstructured":"Lovell DJ, Ruperto N, Mouy R, Paz E, Rubio-Perez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, et al. Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years. Arthritis Rheumatol. 2015;67(10):2759\u201370.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"1728_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/art.24087","volume":"61","author":"HM Albers","year":"2009","unstructured":"Albers HM, Wessels JA, van der Straaten RJ, Brinkman DM, Suijlekom-Smit LW, Kamphuis SS, Girschick HJ, Wouters C, Schilham MW, le Cessie S, et al. Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. Arthritis Rheum. 2009;61(1):46\u201351.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1728_CR14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/acr.20460","volume":"63","author":"T Beukelman","year":"2011","unstructured":"Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011;63(4):465\u201382.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"21","key":"1728_CR15","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1001\/jama.2011.1671","volume":"306","author":"MH Otten","year":"2011","unstructured":"Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M, Koopman-Keemink Y, Gorter SL, Dolman KM, Swart JF, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA. 2011;306(21):2340\u20137.","journal-title":"JAMA"},{"issue":"6","key":"1728_CR16","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1002\/art.34343","volume":"64","author":"CA Wallace","year":"2012","unstructured":"Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O\u2019Neil KM, Zeft AS, Szer IS, Ringold S, Brunner HI, Schanberg LE, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012;64(6):2012\u201321.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"1728_CR17","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1136\/annrheumdis-2014-205372","volume":"74","author":"J Guzman","year":"2015","unstructured":"Guzman J, Oen K, Tucker LB, Huber AM, Shiff N, Boire G, Scuccimarri R, Berard R, Tse SM, Morishita K, et al. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis. 2015;74(10):1854\u201360.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1728_CR18","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1136\/annrheumdis-2014-206034","volume":"75","author":"AM Selvaag","year":"2016","unstructured":"Selvaag AM, Aulie HA, Lilleby V, Flato B. Disease progression into adulthood and predictors of long-term active disease in juvenile idiopathic arthritis. Ann Rheum Dis. 2016;75(1):190\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1728_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.acap.2013.11.007","volume":"14","author":"N Sharma","year":"2014","unstructured":"Sharma N, O\u2019Hare K, Antonelli RC, Sawicki GS. Transition care: future directions in education, health policy, and outcomes research. Acad Pediatr. 2014;14(2):120\u20137.","journal-title":"Acad Pediatr"},{"issue":"2","key":"1728_CR20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.semarthrit.2017.05.003","volume":"47","author":"A Luque Ramos","year":"2017","unstructured":"Luque Ramos A, Hoffmann F, Albrecht K, Klotsche J, Zink A, Minden K. Transition to adult rheumatology care is necessary to maintain DMARD therapy in young people with juvenile idiopathic arthritis. Semin Arthritis Rheum. 2017;47(2):269\u201375.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"1728_CR21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.reumae.2011.06.001","volume":"8","author":"Isabel Castrej\u00f3n","year":"2012","unstructured":"Castrej\u00f3n I: Transitional care programs for patients with rheumatic diseases: review of the literature [in Spanish]. Reumatol Clin 2012, 8(1):20\u201326.","journal-title":"Reumatolog\u00eda Cl\u00ednica (English Edition)"},{"issue":"10","key":"1728_CR22","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s00296-015-3273-6","volume":"35","author":"I Calvo","year":"2015","unstructured":"Calvo I, Anton J, Bustabad S, Camacho M, de Inocencio J, Gamir ML, Grana J, La Cruz L, Robledillo JC, Medrano M, et al. Consensus of the Spanish Society of Pediatric Rheumatology for transition management from pediatric to adult care in rheumatic patients with childhood onset. Rheumatol Int. 2015;35(10):1615\u201324.","journal-title":"Rheumatol Int"},{"issue":"4","key":"1728_CR23","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/annrheumdis-2016-210112","volume":"76","author":"HE Foster","year":"2017","unstructured":"Foster HE, Minden K, Clemente D, Leon L, McDonagh JE, Kamphuis S, Berggren K, van Pelt P, Wouters C, Waite-Jones J, et al. EULAR\/PReS standards and recommendations for the transitional care of young people with juvenile-onset rheumatic diseases. Ann Rheum Dis. 2017;76(4):639\u201346.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1728_CR24","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1093\/rheumatology\/ket248","volume":"52","author":"F McErlane","year":"2013","unstructured":"McErlane F, Foster HE, Davies R, Lunt M, Watson KD, Symmons DP, Hyrich KL. Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2013;52(10):1905\u201313.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"1728_CR25","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10067-012-2135-9","volume":"32","author":"D Hilderson","year":"2013","unstructured":"Hilderson D, Eyckmans L, Van der Elst K, Westhovens R, Wouters C, Moons P. Transfer from paediatric rheumatology to the adult rheumatology setting: experiences and expectations of young adults with juvenile idiopathic arthritis. Clin Rheumatol. 2013;32(5):575\u201383.","journal-title":"Clin Rheumatol"},{"issue":"5 Suppl 85","key":"1728_CR26","first-page":"S163","volume":"32","author":"L Carmona","year":"2014","unstructured":"Carmona L, de la Vega M, Ranza R, Casado G, Titton DC, Descalzo M\u00c1, G\u00f3mez-Reino J. BIOBADASER, BIOBADAMERICA, and BIOBADADERM: safety registers sharing commonalities across diseases and countries. Clin Exp Rheumatol. 2014;32(5 Suppl 85):S163\u20137.","journal-title":"Clin Exp Rheumatol"},{"key":"1728_CR27","doi-asserted-by":"publisher","unstructured":"Sanchez-Piedra C, Hern\u00e1ndez Miguel MV, Manero J, Rosell\u00f3 R, S\u00e1nchez-Costa JT, Rodr\u00edguez-Lozano C, Campos C, Cuende E, Fern\u00e1ndez-Lopez JC, Bustabad S, Mart\u00edn Domenech R, P\u00e9rez-Pamp\u00edn E, Del Pino-Montes J, Millan-Arciniegas AM, D\u00edaz-Gonz\u00e1lez F, G\u00f3mez-Reino JJ; en representaci\u00f3n del Grupo de trabajo BIOBADASER Fase III. Objectives and methodology of BIOBADASER phase iii. Reumatol Clin. 2017. \n                    https:\/\/doi.org\/10.1016\/j.reuma.2017.08.001\n                    \n                  . [Epub ahead of print] English, Spanish.","DOI":"10.1016\/j.reuma.2017.08.001"},{"issue":"2","key":"1728_CR28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109\u201317.","journal-title":"Drug Saf"},{"issue":"8","key":"1728_CR29","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, Nemcova D, Mouy R, Sandborg C, Bohnsack J, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810\u201320.","journal-title":"N Engl J Med"},{"issue":"5","key":"1728_CR30","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/art.23427","volume":"58","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, Baumgartner SW, Giannini EH. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58(5):1496\u2013504.","journal-title":"Arthritis Rheum"},{"issue":"9636","key":"1728_CR31","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","volume":"372","author":"N Ruperto","year":"2008","unstructured":"Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(9636):383\u201391.","journal-title":"Lancet"},{"issue":"11","key":"1728_CR32","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/rheumatology\/kex265","volume":"56","author":"D Dimopoulou","year":"2017","unstructured":"Dimopoulou D, Trachana M, Pratsidou-Gertsi P, Sidiropoulos P, Kanakoudi-Tsakalidou F, Dimitroulas T, Garyfallos A. Predictors and long-term outcome in Greek adults with juvenile idiopathic arthritis: a 17-year continuous follow-up study. Rheumatology. 2017;56(11):1928\u201338.","journal-title":"Rheumatology"},{"key":"1728_CR33","unstructured":"Harnett T. Who will treat arthritis in 2005? Rheumatologist. 2007;(1). \n                    https:\/\/www.the-rheumatologist.org\/article\/who-will-treat-arthritis-in-2005\/\n                    \n                  ."},{"issue":"3","key":"1728_CR34","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/art.10863","volume":"48","author":"HE Foster","year":"2003","unstructured":"Foster HE, Marshall N, Myers A, Dunkley P, Griffiths ID. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum. 2003;48(3):767\u201375.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"1728_CR35","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1002\/art.10444","volume":"46","author":"K Minden","year":"2002","unstructured":"Minden K, Niewerth M, Listing J, Biedermann T, Bollow M, Schontube M, Zink A. Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum. 2002;46(9):2392\u2013401.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"1728_CR36","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1093\/rheumatology\/41.12.1428","volume":"41","author":"JC Packham","year":"2002","unstructured":"Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford). 2002;41(12):1428\u201335.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"1728_CR37","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1093\/rheumatology\/kev195","volume":"54","author":"J Anink","year":"2015","unstructured":"Anink J, Prince FH, Dijkstra M, Otten MH, Twilt M, ten Cate R, Gorter SL, Koopman-Keemink Y, van Rossum MA, Hoppenreijs EP, et al. Long-term quality of life and functional outcome of patients with juvenile idiopathic arthritis in the biologic era: a longitudinal follow-up study in the Dutch Arthritis and Biologicals in Children Register. Rheumatology (Oxford). 2015;54(11):1964\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"1728_CR38","doi-asserted-by":"publisher","first-page":"e000273","DOI":"10.1136\/rmdopen-2016-000273","volume":"2","author":"L Kearsley-Fleet","year":"2016","unstructured":"Kearsley-Fleet L, McErlane F, Foster HE, Lunt M, Watson KD, Symmons DP, Hyrich KL. Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritis. RMD Open. 2016;2(2):e000273.","journal-title":"RMD Open"},{"issue":"8","key":"1728_CR39","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1093\/rheumatology\/kes019","volume":"51","author":"K Minden","year":"2012","unstructured":"Minden K, Niewerth M, Zink A, Seipelt E, Foeldvari I, Girschick H, Ganser G, Horneff G. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology (Oxford). 2012;51(8):1407\u201315.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1728_CR40","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/rheumatology\/keq292","volume":"50","author":"V Papsdorf","year":"2011","unstructured":"Papsdorf V, Horneff G. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology (Oxford). 2011;50(1):214\u201321.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"1728_CR41","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1093\/rheumatology\/kev398","volume":"55","author":"AF Mour\u00e3o","year":"2015","unstructured":"Mour\u00e3o AF, Santos MJ, Melo Gomes JA, Martins FM, Mendon\u00e7a SC, Oliveira Ramos F, Fernandes S, Salgado M, Guedes M, Carvalho S. Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt. Rheumatology. 2015;55(4):697\u2013703.","journal-title":"Rheumatology"},{"issue":"8","key":"1728_CR42","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s10067-017-3712-8","volume":"36","author":"EG Favalli","year":"2017","unstructured":"Favalli EG, Pontikaki I, Becciolini A, Biggioggero M, Ughi N, Romano M, Crotti C, Gattinara M, Gerloni V, Marchesoni A, et al. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences. Clin Rheumatol. 2017;36(8):1747\u201355.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"1728_CR43","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12969-016-0126-0","volume":"14","author":"S Verazza","year":"2016","unstructured":"Verazza S, Davi S, Consolaro A, Bovis F, Insalaco A, Magni-Manzoni S, Nicolai R, Marafon DP, De Benedetti F, Gerloni V, et al. Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. Pediatr Rheumatol Online J. 2016;14(1):68.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"6","key":"1728_CR44","doi-asserted-by":"publisher","first-page":"278","DOI":"10.4081\/reumatismo.2013.682","volume":"65","author":"M Romano","year":"2014","unstructured":"Romano M, Pontikaki I, Gattinara M, Ardoino I, Donati C, Boracchi P, Meroni PL, Gerloni V. Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients. Reumatismo. 2014;65(6):278\u201385.","journal-title":"Reumatismo"},{"issue":"Suppl 17","key":"1728_CR45","first-page":"S27","volume":"15","author":"T Pincus","year":"1997","unstructured":"Pincus T, Stein CM. Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: some explanations and suggestions for future studies. Clin Exp Rheumatol. 1997;15(Suppl 17):S27\u201338.","journal-title":"Clin Exp Rheumatol"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1728-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-018-1728-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1728-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T19:11:11Z","timestamp":1570648271000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-018-1728-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,10]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1728"],"URL":"https:\/\/doi.org\/10.1186\/s13075-018-1728-3","relation":{},"ISSN":["1478-6362"],"issn-type":[{"type":"electronic","value":"1478-6362"}],"subject":[],"published":{"date-parts":[[2018,10,10]]},"assertion":[{"value":"16 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki. Ethics approval for the study was obtained from Hospital Clinic (Barcelona, Spain). The institutional review board at each participating center approved the protocol.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"227"}}